FY2022 EPS Estimates for Allogene Therapeutics, Inc. Raised by Zacks Research (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLOGet Rating) – Research analysts at Zacks Research lifted their FY2022 EPS estimates for shares of Allogene Therapeutics in a note issued to investors on Wednesday, November 16th. Zacks Research analyst S. Ganoria now anticipates that the company will earn ($2.41) per share for the year, up from their previous forecast of ($2.48). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($2.38) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q4 2022 earnings at ($0.75) EPS, Q1 2023 earnings at ($0.75) EPS, Q2 2023 earnings at ($0.76) EPS, Q3 2023 earnings at ($0.78) EPS, Q4 2023 earnings at ($0.79) EPS, FY2023 earnings at ($3.08) EPS, Q1 2024 earnings at ($0.81) EPS, Q2 2024 earnings at ($0.79) EPS, Q3 2024 earnings at ($0.78) EPS and FY2024 earnings at ($2.96) EPS.

Several other brokerages have also issued reports on ALLO. Oppenheimer cut their target price on shares of Allogene Therapeutics to $32.00 in a research report on Thursday, October 13th. B. Riley lowered their target price on shares of Allogene Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, September 22nd. JMP Securities restated a “buy” rating and issued a $23.00 price target on shares of Allogene Therapeutics in a research report on Tuesday, September 27th. Raymond James cut shares of Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 10th. Finally, Truist Financial reduced their price target on shares of Allogene Therapeutics to $29.00 in a research report on Tuesday, August 23rd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.10.

Allogene Therapeutics Trading Up 2.3 %

Shares of NASDAQ ALLO opened at $10.24 on Monday. The firm has a 50 day moving average of $10.79 and a 200 day moving average of $11.41. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -4.65 and a beta of 0.59. Allogene Therapeutics has a 12-month low of $6.43 and a 12-month high of $19.25.

Allogene Therapeutics (NASDAQ:ALLOGet Rating) last posted its earnings results on Wednesday, November 2nd. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.04. Allogene Therapeutics had a negative net margin of 126,580.16% and a negative return on equity of 37.74%. During the same period in the previous year, the business posted ($0.57) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. CI Investments Inc. grew its position in shares of Allogene Therapeutics by 80.5% during the second quarter. CI Investments Inc. now owns 2,193 shares of the company’s stock worth $25,000 after buying an additional 978 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Allogene Therapeutics during the third quarter worth approximately $34,000. US Bancorp DE lifted its stake in Allogene Therapeutics by 41.9% in the second quarter. US Bancorp DE now owns 5,474 shares of the company’s stock valued at $63,000 after buying an additional 1,616 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in Allogene Therapeutics in the third quarter valued at approximately $67,000. Finally, Penserra Capital Management LLC purchased a new stake in Allogene Therapeutics in the first quarter valued at approximately $66,000. Hedge funds and other institutional investors own 84.81% of the company’s stock.

Allogene Therapeutics Company Profile

(Get Rating)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

See Also

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.